TLDR
- Gilead Sciences stock has gained roughly 35% over the past year, trading recently around $147.82.
- The company’s HIV drug Biktarvy and newer prophylactic treatment Yeztugo are driving strong revenue growth.
- Gilead raised its full-year sales guidance to between $30.1 billion and $30.4 billion.
- Confluence Investment Management trimmed its stake by 5% in the third quarter, though most analysts remain bullish.
- Twenty-three analysts rate the stock a Buy, with an average price target of $158.78.
Gilead Sciences stock (GILD) has climbed about 35% over the past year. Shares recently traded at $147.82, down slightly on the day.
That rise has lagged the broader biotech sector, but the company’s underlying business tells a steady story. Its HIV franchise keeps growing, and new drugs are starting to add real weight to the top line.
Biktarvy, Gilead’s flagship HIV treatment, brought in $3.8 billion in sales last quarter alone. That’s a big number for a single drug, and it keeps climbing year over year.
Yeztugo, a newer prophylactic medicine, helped push that category over $1 billion in sales for the first time. Not bad for a product still finding its footing.
Earnings and Guidance
Gilead’s most recent quarterly report came in on August 3rd. The company posted a loss of $6.75 per share, but that beat analyst expectations of a $7.25 loss.
Revenue came in at $7.8 billion, above the $7.4 billion analysts had penciled in. That’s a 10.6% jump from the same quarter last year.
Following that report, Gilead raised its full-year sales guidance to a range of $30.1 billion to $30.4 billion. Some analysts think even that number might be playing it safe.
The company also pays a quarterly dividend of $0.82 per share, working out to a 2.2% yield. That dividend was paid out on September 29th.
Analyst and Insider Activity
Wall Street remains mostly upbeat. Twenty-three analysts currently rate the stock a Buy, while six have it at Hold. That adds up to a “Moderate Buy” consensus, with an average price target of $158.78.
Morgan Stanley trimmed its target slightly to $165, still keeping an “overweight” rating. Needham & Company set a more ambitious target of $170, also with a Buy rating.
Not everyone’s piling in further, though. Confluence Investment Management cut its position by 5% in the third quarter, selling just over 41,000 shares. The firm still holds nearly 791,300 shares worth about $117.9 million.
Insider selling has also picked up. CEO Daniel O’Day sold 15,000 shares in early September at an average price of $148.64, netting over $2.2 million.
Another executive, Johanna Mercier, sold 28,000 shares in August at $137.64 each. Combined, insiders have sold 90,000 shares worth about $12.7 million over the past 90 days.
Despite that selling, institutional ownership remains heavy. Institutions collectively own nearly 84% of the company’s stock.
On the pipeline side, Gilead is working on a once-weekly HIV treatment developed alongside Merck. That drug could see approval in the coming months, adding another leg to its HIV business.
The stock trades at around 15 times next year’s expected earnings. That’s not a stretch valuation by biotech standards, especially with EPS expected to climb to $10.66 by 2028.
Debt has grown due to recent acquisitions, and drug pricing remains a watch item for the sector broadly. Gilead’s 50-day moving average sits at $142.99, with a 200-day average of $136.47.
Shares have ranged between $108.46 and $157.29 over the past year. Market cap currently stands at $183.29 billion.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
